Supplementary Figure S3 from The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer

Abstract
Figure S3. PSMA-11 does not compete with AMG 160 for PSMA binding.